Pharmaron Beijing Co., Ltd.*

康龍化成(北京)新藥技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

(1) PROPOSED REDUCTION OF REGISTERED CAPITAL (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) PROPOSED AMENDMENTS TO VARIOUS SETS OF INTERNAL RULES AND REGULATIONS AND (4) PROPOSED APPOINTMENT OF INTERNAL CONTROL AUDITOR

The board of directors (the "**Board**") of Pharmaron Beijing Co., Ltd.* (the "**Company**") hereby announces that, it has proposed at the meeting of the Board held on Tuesday, December 21, 2021 to seek the approval of the shareholders of the Company at the extraordinary general meeting to be convened to approve, among others:

(1) the repurchase and cancellation of 132,012 restricted A shares granted under the A share incentive scheme adopted by the Company on August 15, 2019 (the "**A Share Incentive Scheme**") due to the resignation of two grantees of such restricted A shares (the "**Proposed Repurchase and Cancellation**") in accordance with the provisions of the A Share Incentive Scheme. The reduction of registered capital of the Company from RMB794,177,098 to RMB794,045,086 and the decrease of number of issued shares of the Company from 794,177,098 shares to 794,045,086 shares, upon approval by the shareholders and completion of the Proposed Repurchase and Cancellation (the "**Proposed Reduction of Registered Capital**").

(2) the following proposed amendments (the "**Proposed Amendments to Articles**") to the Articles of Association of the Company in light of, among others, the Proposed Repurchase and Cancellation and the Proposed Reduction of Registered Capital.

Table of Comparison of the Proposed Amendments to the Articles

Before Amendment	After Amendment
Article 6 The registered capital of the Company is RMB794,177,098.	**Article 6** The registered capital of the Company is RMB**794,045,086**.
Article 21 The shareholding structure of the Company is: 794,177,098 ordinary shares, including 660,160,598 shares held by holders of domestic-listed domestic shares, and 134,016,500 shares held by holders of H shares.	**Article 21** The shareholding structure of the Company is: **794,045,086** ordinary shares, including **660,028,586** shares held by holders of domestic-listed domestic shares, and 134,016,500 shares held by holders of H shares.
Article 79 When a shareholders' general meeting is convened by the Company, the board of directors, the supervisory committee or shareholders individually or jointly holding 3% or more of the shares of the Company shall be entitled to raise proposals to the Company. Shareholders individually or jointly holding 3% or more of the shares of the Company may submit ad hoc proposed resolutions in writing to the convener of the general meeting 10 days before the convening of the general meeting. The convener shall issue a supplemental notice of the general meeting within 2 days upon receipt of the proposals and announce the contents thereof. Except for circumstances provided in the above paragraph, the convener, after issuing the notice and announcement of the general meeting, shall neither revise the proposals stated in the notice of general meetings nor add new proposals. The general meeting shall neither vote nor make a resolution on any proposals that are not included in the notice or are inconsistent with Article 78 hereof.	**Article 79** When a general meeting is convened by the Company, the board of directors, the supervisory committee or shareholders individually or jointly holding 3% or more of the shares of the Company shall be entitled to raise proposals to the Company. Shareholders individually or jointly holding 3% or more of the shares of the Company may submit ad hoc proposed resolutions in writing to the convener of the general meeting 10 days before the convening of the general meeting. The convener shall issue a supplemental notice of the general meeting within 2 days upon receipt of the proposals and announce the contents thereof. **If the notice period of the supplemental notice fails to meet the relevant provisions of the listing rules of the stock exchange where the Company's shares are listed, the convener shall postpone the convening of the general meeting and issue the notice of extension in accordance with the listing rules of the stock exchange where the Company's shares are listed and the Articles of Association.** Except for circumstances provided in the above paragraph, the convener, after issuing the notice and announcement of the general meeting, shall neither revise the proposals stated in the notice of general meetings nor add new proposals. The general meeting shall neither vote nor make a resolution on any proposals that are not included in the notice or are inconsistent with Article 78 hereof.

<table>
<tr><td>

Article 105 The following matters shall be passed by way of an ordinary resolution at a shareholders' general meeting:

(I) Work reports of the board of directors and the supervisory committee;

(II) Profit distribution plan and loss recovery plan formulated by the board of directors;

(III) Appointment and removal of members of the board of directors and members of the supervisory committee, their remuneration and method of payment thereof;

(IV) Proposed annual preliminary financial budgets, final account proposals, balance sheets, statement of income and other financial statements of the Company;

(V) Annual reports of the Company;

(VI) Matters other than those requiring the approval by way of special resolutions in accordance with the provisions of the laws, administrative regulations, listing rules of the place where the shares of the Company are listed or the Articles of Association.

</td><td>

Article 105 The following matters shall be passed by way of an ordinary resolution at a shareholders' general meeting:

(I) Work reports of the board of directors and the supervisory committee;

(II) Profit distribution plan and loss recovery plan formulated by the board of directors;

(III) Appointment and removal of members of the board of directors and members of the supervisory committee, their remuneration and method of payment thereof;

(IV) Proposed annual preliminary financial budgets, final account proposals, balance sheets, statement of income and other financial statements of the Company;

(V) Annual reports of the Company;

(VI) Appointment, removal and remuneration of accounting firms;

(VII) Matters other than those requiring the approval by way of special resolutions in accordance with the provisions of the laws, administrative regulations, listing rules of the place where the shares of the Company are listed or the Articles of Association.

</td></tr>
</table>

Article 141 The methods and procedures to nominate directors are as follows: (I) the candidates for directors (excluding independent directors) of the board of directors shall be nominated by the board of directors or shareholder(s) severally or jointly holding more than 3% of the total number of the voting shares of the Company, and shall be elected at a general meeting of the Company. (II) the candidates for independent directors shall be nominated in the way and procedure as specified by laws, administrative regulations, departmental rules, listing rules of the stock exchange where the Company's shares are listed or the Articles of Association. (III) the written notice on intention for nominating candidates for directors and candidates' willingness to accept the nominations shall be sent to the Company no earlier than the issue date of the notice of the general meeting and no later than the 7th day prior to the convention of the general meeting. The Company shall give relevant nominees and candidates for directors at least seven days to submit the aforesaid notice and document (this period is calculated from the day after the issue date of the notice of the general meeting). The candidates for directors who accept the nominations shall promise that the information publicly disclosed about them is true and complete, and that they will diligently fulfill the duties as directors if elected.	**Article 141** The methods and procedures to nominate directors are as follows: (I) the candidates for directors (excluding independent directors) of the board of directors shall be nominated by the board of directors or shareholder(s) severally or jointly holding more than 3% of the total number of the voting shares of the Company, and shall be elected at a general meeting of the Company. (II) the candidates for independent directors shall be nominated in the way and procedure as specified by laws, administrative regulations, departmental rules, listing rules of the stock exchange where the Company's shares are listed or the Articles of Association. (III) the written notice on intention for nominating candidates for directors and candidates' willingness to accept the nominations shall be sent to the Company no earlier than the issue date of the notice of the general meeting and no later than the 7th day prior to the convention of the general meeting. **Where relevant nominees are nominated as directors in accordance with the provisions of this Article, relevant proposals shall comply with the relevant provisions of Article 79 of the Articles of Association.** The Company shall give relevant nominees and candidates for directors at least seven days to submit the aforesaid notice and document (this period is calculated from the day after the issue date of the notice of the general meeting). The candidates for directors who accept the nominations shall promise that the information publicly disclosed about them is true and complete, and that they will diligently fulfill the duties as directors if elected.

(3) the proposed amendments to various sets of internal rules and regulations of the Company (the "**Proposed Amendments to Internal Rules**"), including: (i) the Rules of Procedure for General Meetings; (ii) the Rules of Procedures for Board Meetings; (iii) the Rules of Procedures for the Supervisory Committee; (iv) the Related Party Transactions Management Policy; (v) the External Guarantee Management Policy; (vi) the Independent Non-executive Directors Working Policy; (vii) the External Investments Management Policy; and (viii) the Procedures for a Shareholder to Nominate a Person for Election as a Director, all of which the amendments will be proposed to the shareholders of the Company at an extraordinary general meeting to be convened by the Company. The full texts of these internal rules and regulations of the Company are listed in appendices to the circular to be dispatched to the shareholders of the Company.

    The English translation of these internal rules and regulations is for reference only. If there are discrepancies between the Chinese and English texts, the Chinese version shall prevail.

(4) the proposed appointment of Ernst & Young as the Company's internal control auditor ("**Proposed Appointment of Internal Control Auditor**") for the year of 2021, to conduct internal control auditing and issue an internal control auditing report for the Company, with the auditing fee amounting to RMB460,000, subject to the approval of the shareholders of the Company.

GENERAL INFORMATION

A circular containing, among other things, details about the Proposed Repurchase and Cancellation, the Proposed Reduction of Registered Capital, the Proposed Amendments to Articles, the Proposed Amendments to Internal Rules and the Proposed Appointment of Internal Control Auditor will be despatched to the shareholders of the Company as soon as practicable.

By order of the Board
Pharmaron Beijing Co., Ltd.*
康龍化成（北京）新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
December 21, 2021

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

* *For identification purposes only*